About: Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 July 1993

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в липні 1993 (uk) article scientifique publié en 1993 (fr) im Juli 1993 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunetu de 1993 (ast) scientific article published on 01 July 1993 (en)
publication date	wds:Q72224793-2C47894E-D15B-4B0A-96D4-251AEC368BCC
publication date	1993-07-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q72224793-7177EE14-F0B8-4170-A703-149376AC6C24
language of work or name	English
author name string	wds:Q72224793-274A585A-8B3C-4520-AC2D-EAC5551D427D wds:Q72224793-7C7D02B5-BEFB-4C2C-AA1F-85E329958D7A wds:Q72224793-98F2472E-DB58-4344-B550-E36465DD408D wds:Q72224793-AAC62106-8A0A-40F6-AB0D-77A71FD89203 wds:Q72224793-D4C1EB71-E4AD-48D9-B083-BBC13DCE554B wds:Q72224793-DB59D90A-3CAF-4CB8-B61D-AF08F3161165 wds:Q72224793-EA28F8B8-FDDA-41C8-828C-A5371C39DB35 wds:Q72224793-FBAAE110-22FF-4A95-9779-469E2BDCD0DB
author name string	D Stablein D H Schwartz P Berman R Sposto M L Clements A M Duliege A Izu T Twaddell
rdfs:label	Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine (en) Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine (nl)
skos:prefLabel	Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine (en) Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine (nl)
name	Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine (en) Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine (nl)
author	wds:Q72224793-A29D41AC-3C2F-46CC-AD73-898D6EF323B1 wds:Q72224793-A6400707-3515-45D5-AA8B-71DEB726E5FC
author	Robert B Belshe Geoffrey J Gorse
title	wds:Q72224793-23CB1BC6-0FE9-4D8E-80B2-1A94C77C29C5
title	Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine (en)
page(s)	wds:Q72224793-80DF9567-BBB6-4A49-9642-94DD6CF37439
page(s)	69-73
instance of	wds:Q72224793-84EB2AAE-4C0E-4C1B-B3EA-4927E856B02A
instance of	scholarly article
PubMed ID	wds:Q72224793-0CB3AD1A-2080-49CB-A6A9-E67466FB2F59
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8100910
PubMed ID	8100910
published in	wds:Q72224793-A00B9A52-B44E-42CA-AD24-AC0147F0A359
published in	The Lancet
issue	wds:Q72224793-603972B3-1A2E-4B5D-99A8-D7D179E8059D
volume	wds:Q72224793-7CDC58A9-C86B-496E-B0D1-A91ED831C5CC
issue	8863
volume	342
DOI	wds:Q72224793-BA9B93B1-42B0-49A0-8C53-0A3C0CDBF9CB
DOI	http://dx.doi.org/10.1016/0140-6736(93)91283-R
DOI	10.1016/0140-6736(93)91283-R
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q72224793
is cites work of	Poxvirus vectors as HIV/AIDS vaccines in humans A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. HIV-1 neutralizing antibodies: understanding nature's pathways Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1 Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140 Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120. HIV preventive vaccines. Progress to date Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. DNA gene vaccination for HIV. Virus-like particles: designing an effective AIDS vaccine A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge Novel HIV vaccine strategies: overview and perspective Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1). Towards phase III trials for candidate vaccines Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus. Immunoreactivity of chimeric proteins carrying the HIV-1 epitope IGPGRAF. Correlation between predicted conformation and antigenicity. Enhanced activation of human T cell clones specific for virus-like particles expressing the HIV V3 loop in the presence of HIV V3 loop-specific polyclonal antibodies Utility of various commercially available human immunodeficiency virus (HIV) antibody diagnostic kits for use in conjunction with efficacy trials of HIV-1 vaccines Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group Vaccines for viral diseases with dermatologic manifestations HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design. HIV vaccines for prevention of infection and disease in humans A multi-mode chromatographic method for the comparison of the N-glycosylation of a recombinant HIV envelope glycoprotein (gp160s-MN/LAI) purified by two different processes Production of a recombinant monoclonal antibody to Herpes Simplex Virus glycoprotein D for immunoaffinity purification of tagged proteins Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group. Vaccines for control of AIDS--an update
is cites work of	wds:Q33813526-50BC0559-84D7-4A86-BB44-06C2E2F0915B wds:Q33783516-11178913-F580-4715-AC5F-FC3008B55E16 wds:Q37625485-A51C212D-1813-40F7-9FAC-6CD4BCC6B700 wds:Q45783114-7EB62EAE-1D15-44B6-A691-487C746E4E40 wds:Q73781366-DD2B73FA-DF02-43F0-95A4-93DD0C144BB6 wds:Q35848446-49AF3464-AA8A-4A6A-A6A5-0B68B914D430 wds:Q35131573-0EC289DD-5DCE-4FA5-959B-07EA54B23453

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software